Connective Tissue Research
Wolverine Stack — BPC-157 + TB-500 Peptide Stack: Loading & Maintenance Protocol
The most-searched peptide stack. Research interest pairs BPC-157's local tissue signaling with TB-500's broader cell-migration signaling. The program runs 12 weeks: BPC-157 follows its own daily chart, which steps up in Weeks 3–4 and again from Week 5, while TB-500 has its own loading phase (Weeks 1–4) and maintenance phase (Weeks 5–12).
Total program: 12 weeks · 2 individual vials
Why these peptides are researched together
BPC-157 and TB-500 are studied through different, non-overlapping pathways. BPC-157 research centers on local signaling at the tissue — growth-factor activity, nitric oxide pathways and new blood-vessel formation. TB-500 research centers on actin regulation, which governs how cells migrate into an injured area, and on reduced scar formation. One is studied for local signaling, the other for cell movement, so the pair is researched as complementary rather than redundant.
Each peptide at a glance
- BPC-157: 15-amino-acid peptide based on a protein found in gastric juice; studied in tendon, ligament, muscle and bone injury models.
- TB-500 (Thymosin Beta-4 fragment): Short fragment of thymosin beta-4, an actin-binding protein studied for cell migration, new blood-vessel formation and reduced scar formation.
How the schedules fit together
BPC-157 is drawn once daily for the full 12 weeks. TB-500 is drawn only 2 days per week in Weeks 1–4 (for example, Monday and Thursday) and 1 day per week in Weeks 5–12. On TB-500 days both peptides are drawn; on the other days BPC-157 runs alone. Both charts run about 12 weeks, so the two start and finish together.
What the research shows
A 2025 systematic review of 36 BPC-157 studies reported improved functional, structural and biomechanical outcomes in muscle, tendon, ligament and bone injury models. Thymosin beta-4 research describes actin binding, cell migration and reduced scar formation in skin, eye and heart models.
Still unproven
Only 1 of the 36 BPC-157 studies was clinical (a 12-patient retrospective study). No published controlled human study has tested BPC-157 and TB-500 together.
Reported cautions
- Neither BPC-157 nor TB-500 is FDA-approved, and no approved dose exists for either alone or combined.
- Both are prohibited in sport by WADA at all times (BPC-157 class S0, TB-500 class S2).
- No controlled human safety data exists for the combination. Preclinical BPC-157 studies in the 2025 review reported no adverse effects; human safety data remains limited.
- BPC-157 has a reported half-life under 30 minutes, with liver metabolism and kidney clearance.
FAQs
What is the Wolverine Stack?
The most-searched peptide stack. Research interest pairs BPC-157's local tissue signaling with TB-500's broader cell-migration signaling. The program runs 12 weeks: BPC-157 follows its own daily chart, which steps up in Weeks 3–4 and again from Week 5, while TB-500 has its own loading phase (Weeks 1–4) and maintenance phase (Weeks 5–12).
What's in the Wolverine peptide stack?
The Wolverine Stack combines BPC-157 and TB-500, each in its own vial. BPC-157: 15-amino-acid peptide based on a protein found in gastric juice; studied in tendon, ligament, muscle and bone injury models. TB-500: Short fragment of thymosin beta-4, an actin-binding protein studied for cell migration, new blood-vessel formation and reduced scar formation.
What does the Wolverine Stack do?
BPC-157 and TB-500 are studied through different, non-overlapping pathways. BPC-157 research centers on local signaling at the tissue — growth-factor activity, nitric oxide pathways and new blood-vessel formation. TB-500 research centers on actin regulation, which governs how cells migrate into an injured area, and on reduced scar formation. One is studied for local signaling, the other for cell movement, so the pair is researched as complementary rather than redundant.
What is the Wolverine Stack dosage?
The amounts for each peptide are listed week by week in the dosing table on this page, taken from each peptide's full dosing chart, with units on a 100-unit syringe and exact vial counts for the full 12-week program.
What is the Wolverine stack loading phase?
The loading phase applies to TB-500 only. In Weeks 1–4, TB-500 follows its loading chart at 2.0 mg twice weekly (for example, Monday and Thursday). BPC-157 has no loading phase: it follows its daily chart, starting at its lowest amount and stepping up in Weeks 3–4. Exact units are shown in each peptide's row above.
What is the Wolverine stack maintenance phase?
The maintenance phase also applies to TB-500 only: in Weeks 5–12, TB-500 stays at 2.0 mg but drops to once weekly. BPC-157 steps up to its highest chart amount at Week 5 and holds it once daily through Week 12.
Can BPC-157 and TB-500 be mixed in the same syringe?
The Same Syringe Mixing chart lists BPC-157 + TB-500 as leaning compatible: the pair appears in physician-supervised multi-peptide blends and in premade Wolverine blends, though direct analytical testing was not located.
Why does this Wolverine stack use separate BPC-157 and TB-500 vials instead of a premade blend?
A premade Wolverine blend is a fixed 50/50 split, so both peptides always move together. Separate vials allow each amount to be adjusted on its own: TB-500 follows its twice-weekly loading and once-weekly maintenance schedule while BPC-157 follows its daily chart.
How long is a BPC-157 and TB-500 stack cycle?
The full program is 12 weeks. BPC-157 runs once daily for all 12 weeks, increasing at Weeks 3 and 5. TB-500 runs a 4-week loading phase and an 8-week maintenance phase, so both finish at Week 12.
What does research show about BPC-157 and TB-500 together?
Each peptide has its own research: a 2025 systematic review found 36 BPC-157 studies, 35 of them preclinical, and thymosin beta-4 has been reviewed for cell migration and tissue repair in skin, eye and heart models. No published controlled human study has tested the two together.
Is the Wolverine stack FDA-approved?
No. Neither BPC-157 nor TB-500 is FDA-approved for any use, and both are on the World Anti-Doping Agency prohibited list.
Sources
- Vasireddi N, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS Journal, 2025. PMID 40756949
- Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin β4: a multi-functional regenerative peptide. Expert Opin Biol Ther, 2012;12(1):37–51. PMID 22074294
- Drugs.com — What is the Wolverine stack (BPC-157 and TB-500), and is it safe? (medically reviewed, Nov 2026)
- Dr. Henry Sobo, MD — Peptide Stacking Therapy (clinical overview)
- Meto — The 7 Most Popular Peptide Stacks: What the Science Actually Says
Other peptide stacks
- GLOW Peptide Stack
- KLOW Peptide Stack
- CJC-1295 + Ipamorelin Stack
- Tesamorelin + Ipamorelin Stack
- Semax + Selank + NAD+ Stack
- Mitochondrial Peptide Stack
- Tirzepatide + AOD-9604 Stack
- AOD-9604 + MOTS-c Stack
- Epitalon + Pinealon Stack
Educational research reference only. Not medical advice or individualized guidance.